DOCSLIB.ORG

SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia Published OnlineFirst February 26, 2018; DOI: 10.1158/1541-7786.MCR-17-0493 Chromatin, Epigenetics, and RNA Regulation Molecular Cancer Research SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia Shankha Subhra Chatterjee1, Mayukh Biswas1, Liberalis Debraj Boila1, Debasis Banerjee2, and Amitava Sengupta1 Abstract SWI/SNF is an evolutionarily conserved multi-subunit chroma- AML blasts, and loss-of-function studies confirmed transcriptional tin remodeling complex that regulates epigenetic architecture and regulation of Rac GTPase guanine nucleotide exchange factors cellular identity. Although SWI/SNF genes are altered in approx- (GEF) by SMARCB1. Mechanistically, loss of SMARCB1 increased D imately 25% of human malignancies, evidences showing their recruitment of SWI/SNF and associated histone acetyltransferases involvement in tumor cell–autonomous chromatin regulation (HAT) to target loci, thereby promoting H3K27Ac and gene and transcriptional plasticity are limiting. This study demonstrates expression. Together, SMARCB1 deficiency induced GEFs for Rac that human primary acute myeloid leukemia (AML) cells exhibit GTPase activation and augmented AML cell migration and sur- near complete loss of SMARCB1 (BAF47 or SNF5/INI1) and vival. Collectively, these findings highlight tumor suppressor role D D SMARCD2 (BAF60B) associated with nucleation of SWI/SNF . of SMARCB1 and illustrate SWI/SNF function in maintaining an D SMARCC1 (BAF155), an intact core component of SWI/SNF , oncogenic gene expression program in AML. colocalized with H3K27Ac to target oncogenic loci in primary AML cells. Interestingly, gene ontology (GO) term and pathway Implications: Loss of SMARCB1 in AML associates with SWI/ D analysis suggested that SMARCC1 occupancy was enriched on SNF nucleation, which in turn promotes Rac GTPase GEF expres- genes regulating Rac GTPase activation, cell trafficking, and AML- sion, Rac activation, migration, and survival of AML cells, D associated transcriptional dysregulation. Transcriptome profiling highlighting SWI/SNF downstream signaling as important revealed that expression of these genes is upregulated in primary molecular regulator in AML. Mol Cancer Res; 1–14. Ó2018 AACR. Introduction not always inform transcriptional dependencies embedded in tumorigenesis. SWI/SNF (BAF) chromatin remodelers are evolutionarily con- Emerging evidences indicate that SWI/SNF subunits critically served, large (2 MDa) multi-protein complexes, which utilize regulate murine hematopoiesis. Recent studies have shown that energy derived from ATP hydrolysis to mobilize nucleosomes (1). SMARCD2 mediates granulopoiesis through CEBPe-dependent SWI/SNF core components include SMARCB1 (BAF47, SNF5 or mechanism (5, 6). Actl6a (BAF53a) plays essential role in hemato- INI1), SMARCC1/SMARCC2 (BAF155 and BAF170), and one of poietic stem cell (HSC) function (7). Mutant allele of Arid1a the mutually exclusive ATPase subunits, SMARCA4 (BRG1) and (BAF250a) determines pool size of fetal liver HSC populations SMARCA2 (BRM). SWI/SNF complexes often include cell type– (8). In addition, SWI/SNF was also implicated in murine leuke- specific, lineage-restricted subunits, and play important roles in mia development. SMARCA4 was shown to regulate proliferation pluripotency and cellular reprogramming (1, 2). Cancer genome of murine leukemic cells (9, 10). SMARCB1 plays tumor sup- sequencing studies have identified SWI/SNF complexes as one of pressor role in several cancers, and frequent deletion of SMARCB1 the most commonly mutated (25%) chromatin modulators in is observed in chronic myeloid leukemia patients (11). Loss of human cancer (3, 4). However, mutational profiling alone may Smarcb1 in vivo leads to fully penetrant malignant rhabdoid tumors (12, 13). Rac GTPases belong to small Rho GTPase family and are 1 Stem Cell & Leukemia Lab, Cancer Biology & Inflammatory Disorder Division, involved in regulation of a diverse array of cellular functions CSIR-Indian Institute of Chemical Biology, Translational Research Unit of including cell proliferation, survival, adhesion, migration, actin Excellence (TRUE), Salt Lake, Kolkata, West Bengal, India. 2Clinical Hematology, Park Clinic, Gorky Terrace, Kolkata, West Bengal, India. assembly, and transcriptional activation (14, 15). Similar to Ras superfamily proteins, Rac GTPases cycle between inactive GDP- Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/). bound and active GTP-bound conformations, regulated by spe- cific guanine nucleotide exchange factors (GEF), to transduce S.S. Chatterjee and M. Biswas contributed equally to this article. signals to effector proteins (14). Recent studies have suggested Corresponding Author: Amitava Sengupta, CSIR-Indian Institute of Chemical that Rac GTPases play integral roles in myeloid leukemia cell Biology, Kolkata 700091, India. Phone: 9133-2473-0492; Fax: 9133-2473-5197; homing, engraftment, survival, and trafficking within the bone E-mail: [email protected] marrow microenvironment (15–18). Attenuation of Rac GTPase doi: 10.1158/1541-7786.MCR-17-0493 signaling in synergy with Bcl-2 inhibition has been shown as a Ó2018 American Association for Cancer Research. modality for combination targeted therapy in MLL-AF9 leukemia www.aacrjournals.org OF1 Downloaded from mcr.aacrjournals.org on September 28, 2021. © 2018 American Association for Cancer Research. Published OnlineFirst February 26, 2018; DOI: 10.1158/1541-7786.MCR-17-0493 Chatterjee et al. (19). Myeloid leukemia cells are characterized with elevated Rac and the integrity was assessed on a 0.8% Agarose Gel. Genomic GTP level; however, molecular regulation of Rac activation in DNA with OD260/OD280 >1.8 and OD260/OD230 1.3 was leukemia pathophysiology remains incompletely understood. used for microarray experiments. DNA was considered to be of Here we identify that in human primary acute myeloid good quality when a single clear band was seen when run against a leukemia (AML) cells, SMARCB1 deficiency associates with reference ladder. A total of 0.5 mg of DNA in 10.1 mL was taken into D nucleation of SWI/SNF . SMARCC1, an intact core component a microfuge tube and digestion master mix containing restriction D of SWI/SNF , colocalized with H3K27Ac to target tumor onco- enzymes (Alu I, 5U and Rsa I, 5U) was added. The samples were genic loci, including Rac GTPase GEFs,inAMLcells.Lossof incubated at 37C for 2 hours followed by heat inactivation of D SMARCB1 induced recruitment of SWI/SNF and associated enzymes at 65C for 20 minutes. Samples were labeled using histone acetyltransferases (HAT) to target GEFs for Rac GTPase Agilent sure tag DNA Labeling Kit (catalog no: 5190-3399). activation and promoted AML cell migration. Collectively, Control samples were labeled with Cy3 and test sample with these findings highlight tumor suppressor role of SMARCB1 Cy5. The labeled samples were cleaned up using Amicon Ultra D and illustrate SWI/SNF function in maintaining an oncogenic columns 30-kDa size exclusion filter. DNA yield and incorpo- gene expression program in AML. ration of labeled dye (specific activity) was measured using NanoDrop spectrophotometer. One micrograms each of Cy3- Materials and Methods and Cy5-labeled sample was added with human cot-1 DNA (catalog no. 5190-3393), Agilent aCGH/CoC Blocking agent (part Patient cohort number: 5188-6416), and hybridization buffer (part number: Human AML (n ¼ 67) bone marrow aspirates (1–2 mL each) 5188-6420). The labeled samples in above hybridization mix were obtained from Park Clinic, Kolkata from untreated, freshly were denatured at 95C for 3 minutes and were incubated at 37C diagnosed patients after written, informed consent according to for 30 minutes. The samples were then hybridized at 65C for 24 Institutional Human Ethics Committee (HEC) approval and hours. After hybridization, the slides were washed using Agilent following Indian Institute of Chemical Biology (CSIR-IICB) Insti- aCGH Wash Buffer1 (Agilent Technologies, part number 5188- tutional Review Board (IRB) set guidelines. Sample collection was 5221) at room temperature for 5 minutes and Agilent aCGH Wash part of routine diagnosis and the inclusion criterion for this study Buffer 2 (Agilent Technologies, part number 5188-5222) at 37C was histopathologic confirmation of bone marrow aspirates or for 1 minute. The slides were then washed with acetonitrile (part biopsies, karyotyping, and immunophenotypic analyses (20). number: A2094) for 10 seconds. The microarray slides were Bone marrow aspirates were also collected from age-matched scanned using Agilent Scanner (Agilent Technologies, part num- normal individuals (n ¼ 6) after informed consent, who turned ber G2600D). Image analysis was performed using Agilent Fea- out to be pathologically negative for AML (20). Individual case ture Extraction software, feature extracted raw data was analyzed information is presented in Supplementary Tables S1 and S2. using Agilent Genomic Workbench 7.0 software. The data were Umbilical cord blood samples (40 mL each) were obtained from normalized using Lowess normalization. Significant regions hav- Deb Shishu Nursing Home (Howrah, West Bengal, India) from ing amplification and deletions were identified among each of the term pregnancies after written, informed consent according to samples. Genomic view and chromosome view of the amplifica- CSIR-IICB HEC approval and following IRB set guidelines. Low tion
Load more

Recommended publications
  • SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ
    Published OnlineFirst April 10, 2013; DOI: 10.1158/1535-7163.MCT-13-0005 Molecular Cancer Cancer Therapeutics Insights Therapeutics SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ Monica Brenca1, Sabrina Rossi3, Erica Lorenzetto1, Elena Piccinin1, Sara Piccinin1, Francesca Maria Rossi2, Alberto Giuliano1, Angelo Paolo Dei Tos3, Roberta Maestro1, and Piergiorgio Modena1 Abstract Epithelioid sarcoma is a rare soft tissue neoplasm that usually arises in the distal extremities of young adults. Epithelioid sarcoma presents a high rate of recurrences and metastases and frequently poses diagnostic dilemmas. We previously reported loss of tumor suppressor SMARCB1 protein expression and SMARCB1 gene deletion in the majority of epithelioid sarcoma cases. Unfortunately, no appropriate preclinical models of such genetic alteration in epithelioid sarcoma are available. In the present report, we identified lack of SMARCB1 protein due to a homozygous deletion of exon 1 and upstream regulatory region in epithelioid sarcoma cell line VAESBJ. Restoration of SMARCB1 expression significantly affected VAESBJ cell proliferation, anchorage-independent growth, and cell migration properties, thus supporting the causative role of SMARCB1 loss in epithelioid sarcoma pathogenesis. We investigated the translational relevance of this genetic back- ground in epithelioid sarcoma and showed that SMARCB1 ectopic expression significantly augmented VAESBJ sensitivity to gamma irradiation and acted synergistically with flavopiridol treatment. In VAESBJ, both activated ERBB1/EGFR and HGFR/MET impinged on AKT and ERK phosphorylation. We showed a synergistic effect of combined inhibition of these 2 receptor tyrosine kinases using selective small-molecule inhibitors on cell proliferation. These observations provide definitive support to the role of SMARCB1 inactivation in the pathogenesis of epithelioid sarcoma and disclose novel clues to therapeutic approaches tailored to SMARCB1-negative epithelioid sarcoma.
    [Show full text]
  • Statistical Analysis of the Genomic Distribution and Correlation of Regulatory Elements in the ENCODE Regions
    Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press Letter Statistical analysis of the genomic distribution and correlation of regulatory elements in the ENCODE regions Zhengdong D. Zhang,1 Alberto Paccanaro,2 Yutao Fu,3 Sherman Weissman,5 Zhiping Weng,3,4 Joseph Chang,6 Michael Snyder,7 and Mark B. Gerstein1,8,9 1Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA; 2Department of Computer Science Royal Holloway, University of London, Egham Hill, TW20 0EX, United Kingdom; 3Bioinformatics Program, Boston University, Boston, Massachusetts 02215, USA; 4Biomedical Engineering Department, Boston University, Boston, Massachusetts 02215, USA; 5Department of Genetics, Yale University, New Haven, Connecticut 06510, USA; 6Department of Statistics, Yale University, New Haven, Connecticut 06520, USA; 7Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06520, USA; 8Program in Computational Biology and Bioinformatics Yale University, New Haven, Connecticut 06520, USA The comprehensive inventory of functional elements in 44 human genomic regions carried out by the ENCODE Project Consortium enables for the first time a global analysis of the genomic distribution of transcriptional regulatory elements. In this study we developed an intuitive and yet powerful approach to analyze the distribution of regulatory elements found in many different ChIP–chip experiments on a 10∼100-kb scale. First, we focus on the overall chromosomal distribution of regulatory elements in the ENCODE regions and show that it is highly nonuniform. We demonstrate, in fact, that regulatory elements are associated with the location of known genes. Further examination on a local, single-gene scale shows an enrichment of regulatory elements near both transcription start and end sites.
    [Show full text]
  • Integrase Interactor 1 (INI-1) Deficient Renal Cell Carcinoma
    Open Access Case Report DOI: 10.7759/cureus.13082 Integrase Interactor 1 (INI-1) Deficient Renal Cell Carcinoma Manpreet Singh 1 , Harkirat Singh 1 , Benjamin Hambro 1 , Jasleen Kaur 1 , Ravi Rao 2 1. Internal Medicine, St Agnes Medical Center, Fresno, USA 2. Hematology and Oncology, St Agnes Medical Center, Fresno, USA Corresponding author: Manpreet Singh, [email protected] Abstract Members of the SWItch/sucrose nonfermentable (SWI-SNF) family, including SWI/SNF related, matrix- associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), SWI/SNF related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily B member 1 (SMARCB1)/integrase interactor 1 (INI-1) are known tumor suppressor genes. Interactions between SMARCB1/INI-1 and key protein components in various cellular pathways are related to tumor progression and proliferation. SMARCB1/INI-1 protein was undetectable in rhabdoid tumor cells, whereas non-tumorous cells express the SMARCB1/INI-1 genes. Germline and sporadic mutations of several genes encoding for proteins in this complex are known to cause a spectrum of cancers, usually with sarcomatoid features which include a very aggressive renal medullary carcinoma. We report a case of a 29-year-old male who presented with SMARCA4 deficient renal tumor with a very aggressive clinical behavior which ultimately led to his death. Categories: Nephrology, Oncology Keywords: renal medullary carcinoma, ini-1, renal cell carcinoma, swi/snf, smarcb1, integrase interactor 1 Introduction Renal medullary carcinoma is a rare and very aggressive malignancy affecting young adults with rare cases in patients with sickle cell disease or trait [1]. The tumor arises predominantly in the renal medulla and exhibits a variety of growth patterns including reticular, solid, tubular, trabecular, cribriform, sarcomatoid, and micropapillary [1].
    [Show full text]
  • Sox2-RNA Mechanisms of Chromosome Topological Control in Developing Forebrain
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.22.307215; this version posted September 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Sox2-RNA mechanisms of chromosome topological control in developing forebrain Ivelisse Cajigas1, Abhijit Chakraborty2, Madison Lynam1, Kelsey R Swyter1, Monique Bastidas1, Linden Collens1, Hao Luo1, Ferhat Ay2,3, Jhumku D. Kohtz1,4 1Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Department of Human Molecular Genetics, Stanley Manne Children's Research Institute 2430 N Halsted, Chicago, IL 60614 2Centers for Autoimmunity and Cancer Immunotherapy, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA, 92037, USA 3School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA 4To whom correspondence should be addressed: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.22.307215; this version posted September 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Precise regulation of gene expression networks requires the selective targeting of DNA enhancers. The Evf2 long non-coding RNA regulates Dlx5/6 ultraconserved enhancer(UCE) interactions with long-range target genes, controlling gene expression over a 27Mb region in mouse developing forebrain. Here, we show that Evf2 long range gene repression occurs through multi-step mechanisms involving the transcription factor Sox2, a component of the Evf2 ribonucleoprotein complex (RNP).
    [Show full text]
  • Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer
    diagnostics Article Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer Kung-Chen Ho 1, Jie-Jen Lee 1, Chi-Hsin Lin 2,3, Ching-Hsiang Leung 4 and Shih-Ping Cheng 1,5,* 1 Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei 104215, Taiwan; [email protected] (K.-C.H.); [email protected] (J.-J.L.) 2 Department of Medical Research, MacKay Memorial Hospital, Taipei 104215, Taiwan; [email protected] 3 Department of Bioscience Technology, Chung Yuan Christian University, Taoyuan City 320314, Taiwan 4 Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital and Mackay Medical College, Taipei 104215, Taiwan; [email protected] 5 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan * Correspondence: [email protected]; Tel.: +886-2-2543-3535 Received: 19 April 2020; Accepted: 2 May 2020; Published: 5 May 2020 Abstract: Alterations in the switching defective/sucrose non-fermenting (SWI/SNF) chromatin-remodeling complex are enriched in advanced thyroid cancer. Integrase interactor 1 (INI1), encoded by the SMARCB1 gene on the long arm of chromosome 22, is one of the core subunits of the SWI/SNF complex. INI1 immunohistochemistry is frequently used for the diagnosis of malignant rhabdoid neoplasms. In the present study, we found normal and benign thyroid tissues generally had diffusely intense nuclear immunostaining. Loss of INI1 immunohistochemical expression was observed in 8% of papillary thyroid cancer and 30% of follicular thyroid cancer. Furthermore, loss of INI1 expression was associated with extrathyroidal extension (p < 0.001) and lymph node metastasis (p = 0.038).
    [Show full text]
  • Renal Medullary Carcinomas Depend Upon SMARCB1 Loss And
    RESEARCH ARTICLE Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition Andrew L Hong1,2,3, Yuen-Yi Tseng3, Jeremiah A Wala3, Won-Jun Kim2, Bryan D Kynnap2, Mihir B Doshi3, Guillaume Kugener3, Gabriel J Sandoval2,3, Thomas P Howard2, Ji Li2, Xiaoping Yang3, Michelle Tillgren2, Mahmhoud Ghandi3, Abeer Sayeed3, Rebecca Deasy3, Abigail Ward1,2, Brian McSteen4, Katherine M Labella2, Paula Keskula3, Adam Tracy3, Cora Connor5, Catherine M Clinton1,2, Alanna J Church1, Brian D Crompton1,2,3, Katherine A Janeway1,2, Barbara Van Hare4, David Sandak4, Ole Gjoerup2, Pratiti Bandopadhayay1,2,3, Paul A Clemons3, Stuart L Schreiber3, David E Root3, Prafulla C Gokhale2, Susan N Chi1,2, Elizabeth A Mullen1,2, Charles WM Roberts6, Cigall Kadoch2,3, Rameen Beroukhim2,3,7, Keith L Ligon2,3,7, Jesse S Boehm3, William C Hahn2,3,7* 1Boston Children’s Hospital, Boston, United States; 2Dana-Farber Cancer Institute, Boston, United States; 3Broad Institute of Harvard and MIT, Cambridge, United States; 4Rare Cancer Research Foundation, Durham, United States; 5RMC Support, North Charleston, United States; 6St. Jude Children’s Research Hospital, Memphis, United States; 7Brigham and Women’s Hospital, Boston, United States Abstract Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. We have developed faithful patient-derived RMC models and using whole-genome sequencing, we identified loss-of-function intronic fusion events in one SMARCB1 allele with concurrent loss of the other allele. Biochemical and functional characterization of these models revealed that RMC requires the loss of SMARCB1 for survival.
    [Show full text]
  • Regulation of P27kip1 and P57kip2 Functions by Natural Polyphenols
    biomolecules Review Regulation of p27Kip1 and p57Kip2 Functions by Natural Polyphenols Gian Luigi Russo 1,* , Emanuela Stampone 2 , Carmen Cervellera 1 and Adriana Borriello 2,* 1 National Research Council, Institute of Food Sciences, 83100 Avellino, Italy; [email protected] 2 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 81031 Napoli, Italy; [email protected] * Correspondence: [email protected] (G.L.R.); [email protected] (A.B.); Tel.: +39-0825-299-331 (G.L.R.) Received: 31 July 2020; Accepted: 9 September 2020; Published: 13 September 2020 Abstract: In numerous instances, the fate of a single cell not only represents its peculiar outcome but also contributes to the overall status of an organism. In turn, the cell division cycle and its control strongly influence cell destiny, playing a critical role in targeting it towards a specific phenotype. Several factors participate in the control of growth, and among them, p27Kip1 and p57Kip2, two proteins modulating various transitions of the cell cycle, appear to play key functions. In this review, the major features of p27 and p57 will be described, focusing, in particular, on their recently identified roles not directly correlated with cell cycle modulation. Then, their possible roles as molecular effectors of polyphenols’ activities will be discussed. Polyphenols represent a large family of natural bioactive molecules that have been demonstrated to exhibit promising protective activities against several human diseases. Their use has also been proposed in association with classical therapies for improving their clinical effects and for diminishing their negative side activities. The importance of p27Kip1 and p57Kip2 in polyphenols’ cellular effects will be discussed with the aim of identifying novel therapeutic strategies for the treatment of important human diseases, such as cancers, characterized by an altered control of growth.
    [Show full text]
  • Epidyne®-FRET for Nucleosome Remodeling Assays
    Nucleosome Remodeling Assay by EpiDyne®-FRET EpiDyne®-FRET allows unprecedented access to disease-relevant ATP-dependent chromatin remodeling complexes FIGURE 3 SMARCA 2 SMARCA 4 EpiDyne®-FRET nucleosomes (20 nM) were incubated with Figure 3A Figure 3B chromatin remodeling enzyme (Panel 3A, SMARCA2; panel 3B, SMARCA4) at the indicated concentration in 4.0 3.5 the presence of ATP (2 mM). 3.5 Upon ATP addition, reactions 3.0 were immediately read in 3.0 an Envision Multi-label plate 2.5 reader. Data are presented as 2.5 the mean of the Cy3-Cy5 ratio 2.0 (N=2). 2.0 1.5 Cy3/Cy5 Ratio Cy3/Cy5 1.5 Ratio Cy3/Cy5 1.0 1.0 0 1 2 3 4 5 6 7 8 9 10 0 10 20 30 40 Time, Min Time, Min nM Enzyme nM Enzyme 28 14 7 3.5 0.0 12.50 6.25 3.13 1.56 0 ORDERING INFO Chromatin Remodeling Substrate, Fluorescent Readout Enzymes EpiDyne®-FRET Nucleosome Remodeling Assay Substrate SMARCA2 Chromatin Remodeling Enzyme Catalog No. 16-4201 (Human BRM) Pack Size: 50 μg Catalog No. 15-1015 Pack Size: 100 remodeling rxns Chromatin Remodeling Substrates, Non-Fluorescent Readout SMARCA4 Chromatin Remodeling Enzyme (Human BRG1) ST601-GATC1 ST601-GATC1, 50-N-66, Biotinylated Catalog No. 15-1014 Cat. No. 16-4101 Cat. No.: 16-4114 Pack Size: 100 remodeling rxns Pack Size: 50 μg Pack Size: 50 μg ACF Chromatin Remodeling Enzyme Complex ST601-GATC1, Biotinylated ST601-GATC1,2, 50-N-66, Biotinylated Catalog No. 15-1013 Cat.
    [Show full text]
  • Intrinsic Disorder of the BAF Complex: Roles in Chromatin Remodeling and Disease Development
    International Journal of Molecular Sciences Article Intrinsic Disorder of the BAF Complex: Roles in Chromatin Remodeling and Disease Development Nashwa El Hadidy 1 and Vladimir N. Uversky 1,2,* 1 Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd. MDC07, Tampa, FL 33612, USA; [email protected] 2 Laboratory of New Methods in Biology, Institute for Biological Instrumentation of the Russian Academy of Sciences, Federal Research Center “Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences”, Pushchino, 142290 Moscow Region, Russia * Correspondence: [email protected]; Tel.: +1-813-974-5816; Fax: +1-813-974-7357 Received: 20 September 2019; Accepted: 21 October 2019; Published: 23 October 2019 Abstract: The two-meter-long DNA is compressed into chromatin in the nucleus of every cell, which serves as a significant barrier to transcription. Therefore, for processes such as replication and transcription to occur, the highly compacted chromatin must be relaxed, and the processes required for chromatin reorganization for the aim of replication or transcription are controlled by ATP-dependent nucleosome remodelers. One of the most highly studied remodelers of this kind is the BRG1- or BRM-associated factor complex (BAF complex, also known as SWItch/sucrose non-fermentable (SWI/SNF) complex), which is crucial for the regulation of gene expression and differentiation in eukaryotes. Chromatin remodeling complex BAF is characterized by a highly polymorphic structure, containing from four to 17 subunits encoded by 29 genes. The aim of this paper is to provide an overview of the role of BAF complex in chromatin remodeling and also to use literature mining and a set of computational and bioinformatics tools to analyze structural properties, intrinsic disorder predisposition, and functionalities of its subunits, along with the description of the relations of different BAF complex subunits to the pathogenesis of various human diseases.
    [Show full text]
  • Global Chromatin Changes Resulting from Single-Gene Inactivation—The Role of SMARCB1 in Malignant Rhabdoid Tumor
    cancers Article Global Chromatin Changes Resulting from Single-Gene Inactivation—The Role of SMARCB1 in Malignant Rhabdoid Tumor Colin Kenny 1, Elaine O’Meara 2, Mevlüt Ula¸s 2 , Karsten Hokamp 3 and Maureen J. O’Sullivan 1,2,4,* 1 School of Medicine, Trinity College, University of Dublin, Dublin 2, Ireland; [email protected] 2 The National Children’s Research Centre, O’Sullivan Research Laboratory, Oncology Division, Gate 5, Children’s Health Ireland at Crumlin, D12N512 Dublin, Ireland; [email protected] (E.O.); [email protected] (M.U.) 3 School of Genetics and Microbiology, Trinity College, University of Dublin, Dublin 2, Ireland; [email protected] 4 Histology Laboratory, Pathology Department, Children’s Health Ireland at Crumlin, D12N512 Dublin, Ireland * Correspondence: [email protected] Simple Summary: Malignant rhabdoid tumors (MRT), one of the most lethal, treatment-resistant human cancers, arises in young children within brain, kidney, liver and/or soft tissues. Generally, cancer arises in older adults, and results from multiple significant changes (mutations) accumulating in the genetic blueprint (DNA) of a person’s tissues. This blueprint is composed of a 4-letter alphabet. Together, the multiple significant changes in the blueprint then allow a cell to go “out of control”, becoming a cancer cell. The striking thing about MRT is that it has only a single spelling change, so that mutation must be very powerful to lead to such a lethal cancer. Using a model system that we developed, we show herein how this single mutation alters how the whole of the DNA is arranged, Citation: Kenny, C.; O’Meara, E.; Ula¸s,M.; Hokamp, K.; O’Sullivan, thereby having its profound and lethal effects.
    [Show full text]
  • Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
    Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Wilson, B. G., K. C. Helming, X. Wang, Y. Kim, F. Vazquez, Z. Jagani, W. C. Hahn, and C. W. M. Roberts. 2014. “Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation.” Molecular and Cellular Biology 34 (6): 1136–44. doi:10.1128/MCB.01372-13. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41542741 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation Boris G. Wilson,a Katherine C. Helming,a Xiaofeng Wang,a Youngha Kim,a Francisca Vazquez,c,d Zainab Jagani,f William C. Hahn,c,d,e Charles W. M. Robertsa,b,d,e Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USAa; Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts, USAb; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USAc; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Boston, Massachusetts, USAd; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USAe; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USAf Collectively, genes encoding subunits of the SWI/SNF (BAF) chromatin remodeling complex are mutated in 20% of all human Downloaded from cancers, with the SMARCA4 (BRG1) subunit being one of the most frequently mutated.
    [Show full text]
  • Zytolight ® SPEC SMARCB1/22Q12 Dual Color Probe
    ZytoLight ® SPEC SMARCB1/22q12 Dual Color Probe Background Probe Description Results The ZytoLight ® SPEC SMARCB1/22q12 The SPEC SMARCB1/22q12 Dual Color In a normal interphase nucleus, two oran- Dual Color Probe is designed for the Probe is a mixture of a green fluorochro- ge and two green signals are expected. In detection of deletions of the chromosomal me direct labeled SPEC SMARCB1 probe a cell with deletion of the SMARCB1 gene region harboring the SMARCB1 gene. hybridizing to the human SMARCB1 gene locus, a reduced number of green signals The SMARCB1 (SWI/SNF related, matrix in the chromosomal region 22q11.23 and will be observed. Deletions affecting only associated, actin dependent regulator of an orange fluorochrome direct labeled parts of the SMARCB1 gene might result chromatin, subfamily b, member 1, a.k.a. SPEC 22q12 probe specific for the KRE- in a normal signal pattern with green INI1, SNF5, or BAF47) gene is located on MEN1 (kringle containing transmembrane signals of reduced size. chromosome 22q11.23 and encodes a protein 1) gene region in 22q12.1-q12.2. tumor suppressor. Due to cross-hybridizations of chromoso- Rhabdoid tumors are highly malignant me 22 alpha satellites to other centromeric neoplasms that typically arise in infancy regions, probes specific for 22q12 are and early childhood. They are classified frequently used for chromosome 22 copy as atypical teratoid/rhabdoid tumors (AT/ number detection. RT) when they occur in the CNS or as malignant rhabdoid tumors (MRT) when they are found in renal or extra-renal sites. SMARCB1 22q12 The vast majority of AT/RTs and MRTs are characterized by loss of function of Ideogram of chromosome 22 the SMARCB1 gene due to deletions or indicating the hybridization locations.
    [Show full text]